Comparison of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio levels in ovarian cyst among epithelial ovarian cancer patients at RSUP H. Adam Malik Medan, Indonesia

Abstract

HIGHLIGHTS Neutrophil Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) have potential as independent prognostic markers for ovarian cancer. This research was to evaluated NLR and PLR levels in ovarian cysts with epithelial ovarian cancer patients at RSUP H. Adam Malik Medan.   ABSTRACT Objective: Ovarian cancer is most common malignancy of women and generally diagnosed at advanced stage therefore tends to have poor prognosis. The inflammatory process is proven involved in malignancy mechanism which Neutrophil Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) have potential as independent prognostic markers. This research was to evaluate NLR and PLR levels in ovarian cysts among epithelial ovarian cancer patients at RSUP H. Adam Malik Medan Materials and Methods: This research is a comparative case-control study conducted at Department of Obstetrics and Gynecology at RSUP H. Adam Malik Medan on December 2019 – February 2020. The research sample were 40 patients diagnosed with ovarian cysts and epithelial ovarian cancer, respectively. Bivariate analysis was done with independent T test if data was normally distributed or Mann Whitney if not normally distributed. All results will use a significance value <0.05. Results: Median NLR level in ovarian cancer group was 2.45 (1.06 – 38.44) and in ovarian cysts group was 2.34 (1.44 – 3.78). Median PLR levels in ovarian cancer group was 12813.94 (3178.08 –19040.0) and in ovarian cysts group was 11138.15 (5026.18–22839.51). Based on analysis test, it was found that there was no statistically significant difference of NLR and PLR levels in ovarian cancer compared to ovarian cysts (p>0.05). Conclusion: NLR and PLR levels between ovarian cancer and ovarian cyst patient in RSUP H. Adam Malik Medan shows no difference in value. NLR and PLR can still be used as a marker for malignant process in patient suspected with malignancy.